J. Goldman & Co’s Medicines Co MDCO Stock Holding History

J. Goldman & Co’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-80,000	Closed	-$2.99M	–	380
2015 Q4	$2.99M	Buy	+80,000	New	+$3.02M	0.31%	112

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

J. Goldman & Co's MDCO Position: Q4 2016 in Review

J. Goldman & Co sold out of Medicines Co (MDCO) in Q4 2016, closing a stake of 88,400 shares — an estimated $3.34M sold.

J. Goldman & Co first reported a position in MDCO in Q3 2013 and held it in 8 quarters. The position peaked at $12M in Q1 2014. 195 funds tracked by Wall St. Rank hold MDCO as of Q4 2016.

J. Goldman & Co reported no remaining Medicines Co position as of Q4 2016 after selling out during the quarter.
J. Goldman & Co sold 88,400 Medicines Co shares in Q4 2016, an estimated $3.34M.
J. Goldman & Co first reported a position in Medicines Co in Q3 2013 and held it in 8 quarters.
J. Goldman & Co's Medicines Co position peaked at $12M in Q1 2014.
195 funds tracked by Wall St. Rank held Medicines Co as of Q4 2016.

Based on J. Goldman & Co's 13F filing for Q4 2016, filed 13 Feb 2017.